作者
Giovanni Lampasona,Jonathan Noujaim,Olga Gologan,Jérémie Berdugo,Anastasios Maniakas
摘要
Article Tools MOLECULAR TUMOR BOARD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.21.00561 JCO Precision Oncology no. 6 (2022) e2100561. Published online June 16, 2022. PMID: 35709404 Locoregionally Advanced, BRAF V600L–Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of BRAF and MEK Inhibitors Giovanni Lampasona , BSc1xGiovanni LampasonaSearch for articles by this author; Jonathan Noujaim , MD2xJonathan NoujaimSearch for articles by this author; Olga Gologan, MD3xOlga GologanSearch for articles by this author; Jeremie Berdugo, MD4xJeremie BerdugoSearch for articles by this author; and Anastasios Maniakas , MD, MSc5,6,7xAnastasios ManiakasSearch for articles by this author Show More 1Faculty of Medicine, Sherbrooke University, Sherbrooke, QC, Canada2Department of Oncology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada3Department of Pathology, Montreal University Hospital Center, Montreal, QC, Canada4Department of Pathology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada5Division of Otolaryngology-Head and Neck Surgery, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada6Department of Experimental Surgery, McGill University, Montreal, QC, Canada7Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX https://doi.org/10.1200/PO.21.00561 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Giovanni Lampasona, Anastasios ManiakasProvision of study materials or patients: Jonathan NoujaimCollection and assembly of data: Giovanni Lampasona, Jonathan Noujaim, Jeremie Berdugo, Anastasios ManiakasData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jonathan NoujaimConsulting or Advisory Role: Bayer, NovartisNo other potential conflicts of interest were reported.